

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
15 December 2022 (15.12.2022)



(10) International Publication Number
WO 2022/258805 A1

(51) International Patent Classification:

A61K 38/22 (2006.01) A61P 3/04 (2006.01)
A61K 38/26 (2006.01) A61P 3/06 (2006.01)
C07K 14/435 (2006.01) A61P 3/10 (2006.01)
C07K 14/605 (2006.01) A61P 5/50 (2006.01)
C07K 14/575 (2006.01) A61P 9/12 (2006.01)
A61P 3/00 (2006.01)

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))
— in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(21) International Application Number:

PCT/EP2022/065826

(22) International Filing Date:

10 June 2022 (10.06.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

21178712.2 10 June 2021 (10.06.2021) EP

(71) Applicant: **ANTAG THERAPEUTICS APS** [DK/DK];
Ole Maaloes Vej 3, 2200 Copenhagen N (DK).

(72) Inventors: **HOVARD SPARRE-ULRICH, Alexander**;
Nansensgade 3, 1. th., 1366 Copenhagen K (DK).
ROSENKILDE, Mette Marie; Ole Olsens Allé 30, 2900
Hellerup (DK).

(74) Agent: **HØIBERG P/S**; Adelgade 12, 1304 Copenhagen K
(DK).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS

(57) Abstract: The present invention relates to a glucose-dependent insulinotropic peptide (GIP) receptor (GIPR) antagonist GIP peptide in combination with a glucagon-like peptide-1 (GLP-1) receptor agonist, such as a GLP-1 peptide, for use in the treatment of obesity and obesity-related disorders, as well as GIPR antagonist GIP peptides for treating a subset of obesity-related disorders.

WO 2022/258805 A1